Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Authors:
- Rawan G. FaramandRFRawan G. Faramand
- Sae Bom LeeSLSae Bom Lee
- Michael D. JainMJMichael D. Jain
- Biwei CaoBCBiwei Cao
- Xuefeng WangXWXuefeng Wang
- Kai RejeskiKRKai Rejeski
- Marion SubkleweMarion Subklewe
- Johannes F. FahrmannJFJohannes F. Fahrmann
- Neeraj Y. SainiNSNeeraj Y. Saini
- Samir M. HanashSHSamir M. Hanash
- Yun Pyo KangYKYun Pyo Kang
- Darwin ChangDCDarwin Chang
Open Access
- 8 January 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (2) , 106-113
Abstract
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and inferior clinical responses in 146 patients with DLBCL treated with axicabtagene ciloleucel. We develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) and ferritin to classify patients into low-, intermediate-, and high-risk groups. We observe that patients in the high-risk category were more likely to develop grade ≥3 toxicities and had inferior overall and progression-free survival. We sought to validate our findings with two independent international cohorts demonstrating that patients classified as low-risk have excellent efficacy and safety outcomes. Based on routine and readily available laboratory tests that can be obtained prior to lymphodepleting chemotherapy, this simple risk stratification can inform patient selection for CAR T-cell therapy. Significance: CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes. This article is featured in Selected Articles from This Issue, p. 80Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01-HL167232-01)
This publication has 23 references indexed in Scilit:
- Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphomaNature Medicine, 2022
- The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLJournal for ImmunoTherapy of Cancer, 2022
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphomaBritish Journal of Haematology, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelClinical Cancer Research, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017